Developmental and reproductive toxicity of a recombinant protein subunit COVID-19 vaccine (ZF2001) in rats
ZF2001, a protein subunit vaccine against coronavirus disease 2019 (COVID-19), contains recombinant tandem repeat of dimeric receptor-binding domain (RBD) protein of the SARS-CoV-2 spike protein with an aluminium-based adjuvant. During the development of this vaccine, two nonclinical studies were co...
Saved in:
Published in | npj vaccines Vol. 8; no. 1; p. 74 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
24.05.2023
Nature Publishing Group Nature Portfolio |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | ZF2001, a protein subunit vaccine against coronavirus disease 2019 (COVID-19), contains recombinant tandem repeat of dimeric receptor-binding domain (RBD) protein of the SARS-CoV-2 spike protein with an aluminium-based adjuvant. During the development of this vaccine, two nonclinical studies were conducted to evaluate female fertility, embryo-fetal development, and postnatal developmental toxicity in Sprague‒Dawley rats according to the ICH S5 (R3) guideline. In Study 1 (embryo-fetal developmental toxicity, EFD), 144 virgin female rats were randomly assigned into four groups and received three doses of vaccine (25 μg or 50 μg RBD protein/dose, containing the aluminium-based adjuvant), the aluminium-based adjuvant or a sodium chloride injection administered intramuscularly on days 21 and 7 prior to mating and on gestation day (GD) 6. In Study 2 (pre- and postnatal developmental toxicity, PPND), ZF2001 at a dose of 25 μg RBD protein/dose or sodium chloride injection was administered intramuscularly to female rats (
n
= 28 per group) 7 days prior to mating and on GD 6, GD 20 and postnatal day (PND) 10. There were no obvious adverse effects in dams, except for local injection site reactions related to the aluminium-based adjuvant (yellow nodular deposits in the interstitial muscle fibres). There were also no effects of ZF2001 on the mating performance, fertility or reproductive performance of parental females, embryo-fetal development, postnatal survival, growth, physical development, reflex ontogeny, behavioural and neurofunctional development, or reproductive performance of the offspring. The strong immune responses associated with binding and neutralising antibodies were both confirmed in dams and fetuses or offspring in these two studies. These results would support clinical trials or the use of ZF2001 in maternal immunisation campaigns, including those involving women with childbearing potential, regardless of pregnancy status. |
---|---|
AbstractList | ZF2001, a protein subunit vaccine against coronavirus disease 2019 (COVID-19), contains recombinant tandem repeat of dimeric receptor-binding domain (RBD) protein of the SARS-CoV-2 spike protein with an aluminium-based adjuvant. During the development of this vaccine, two nonclinical studies were conducted to evaluate female fertility, embryo-fetal development, and postnatal developmental toxicity in Sprague‒Dawley rats according to the ICH S5 (R3) guideline. In Study 1 (embryo-fetal developmental toxicity, EFD), 144 virgin female rats were randomly assigned into four groups and received three doses of vaccine (25 μg or 50 μg RBD protein/dose, containing the aluminium-based adjuvant), the aluminium-based adjuvant or a sodium chloride injection administered intramuscularly on days 21 and 7 prior to mating and on gestation day (GD) 6. In Study 2 (pre- and postnatal developmental toxicity, PPND), ZF2001 at a dose of 25 μg RBD protein/dose or sodium chloride injection was administered intramuscularly to female rats (
n
= 28 per group) 7 days prior to mating and on GD 6, GD 20 and postnatal day (PND) 10. There were no obvious adverse effects in dams, except for local injection site reactions related to the aluminium-based adjuvant (yellow nodular deposits in the interstitial muscle fibres). There were also no effects of ZF2001 on the mating performance, fertility or reproductive performance of parental females, embryo-fetal development, postnatal survival, growth, physical development, reflex ontogeny, behavioural and neurofunctional development, or reproductive performance of the offspring. The strong immune responses associated with binding and neutralising antibodies were both confirmed in dams and fetuses or offspring in these two studies. These results would support clinical trials or the use of ZF2001 in maternal immunisation campaigns, including those involving women with childbearing potential, regardless of pregnancy status. ZF2001, a protein subunit vaccine against coronavirus disease 2019 (COVID-19), contains recombinant tandem repeat of dimeric receptor-binding domain (RBD) protein of the SARS-CoV-2 spike protein with an aluminium-based adjuvant. During the development of this vaccine, two nonclinical studies were conducted to evaluate female fertility, embryo-fetal development, and postnatal developmental toxicity in Sprague‒Dawley rats according to the ICH S5 (R3) guideline. In Study 1 (embryo-fetal developmental toxicity, EFD), 144 virgin female rats were randomly assigned into four groups and received three doses of vaccine (25 μg or 50 μg RBD protein/dose, containing the aluminium-based adjuvant), the aluminium-based adjuvant or a sodium chloride injection administered intramuscularly on days 21 and 7 prior to mating and on gestation day (GD) 6. In Study 2 (pre- and postnatal developmental toxicity, PPND), ZF2001 at a dose of 25 μg RBD protein/dose or sodium chloride injection was administered intramuscularly to female rats (n = 28 per group) 7 days prior to mating and on GD 6, GD 20 and postnatal day (PND) 10. There were no obvious adverse effects in dams, except for local injection site reactions related to the aluminium-based adjuvant (yellow nodular deposits in the interstitial muscle fibres). There were also no effects of ZF2001 on the mating performance, fertility or reproductive performance of parental females, embryo-fetal development, postnatal survival, growth, physical development, reflex ontogeny, behavioural and neurofunctional development, or reproductive performance of the offspring. The strong immune responses associated with binding and neutralising antibodies were both confirmed in dams and fetuses or offspring in these two studies. These results would support clinical trials or the use of ZF2001 in maternal immunisation campaigns, including those involving women with childbearing potential, regardless of pregnancy status. Abstract ZF2001, a protein subunit vaccine against coronavirus disease 2019 (COVID-19), contains recombinant tandem repeat of dimeric receptor-binding domain (RBD) protein of the SARS-CoV-2 spike protein with an aluminium-based adjuvant. During the development of this vaccine, two nonclinical studies were conducted to evaluate female fertility, embryo-fetal development, and postnatal developmental toxicity in Sprague‒Dawley rats according to the ICH S5 (R3) guideline. In Study 1 (embryo-fetal developmental toxicity, EFD), 144 virgin female rats were randomly assigned into four groups and received three doses of vaccine (25 μg or 50 μg RBD protein/dose, containing the aluminium-based adjuvant), the aluminium-based adjuvant or a sodium chloride injection administered intramuscularly on days 21 and 7 prior to mating and on gestation day (GD) 6. In Study 2 (pre- and postnatal developmental toxicity, PPND), ZF2001 at a dose of 25 μg RBD protein/dose or sodium chloride injection was administered intramuscularly to female rats (n = 28 per group) 7 days prior to mating and on GD 6, GD 20 and postnatal day (PND) 10. There were no obvious adverse effects in dams, except for local injection site reactions related to the aluminium-based adjuvant (yellow nodular deposits in the interstitial muscle fibres). There were also no effects of ZF2001 on the mating performance, fertility or reproductive performance of parental females, embryo-fetal development, postnatal survival, growth, physical development, reflex ontogeny, behavioural and neurofunctional development, or reproductive performance of the offspring. The strong immune responses associated with binding and neutralising antibodies were both confirmed in dams and fetuses or offspring in these two studies. These results would support clinical trials or the use of ZF2001 in maternal immunisation campaigns, including those involving women with childbearing potential, regardless of pregnancy status. Abstract ZF2001, a protein subunit vaccine against coronavirus disease 2019 (COVID-19), contains recombinant tandem repeat of dimeric receptor-binding domain (RBD) protein of the SARS-CoV-2 spike protein with an aluminium-based adjuvant. During the development of this vaccine, two nonclinical studies were conducted to evaluate female fertility, embryo-fetal development, and postnatal developmental toxicity in Sprague‒Dawley rats according to the ICH S5 (R3) guideline. In Study 1 (embryo-fetal developmental toxicity, EFD), 144 virgin female rats were randomly assigned into four groups and received three doses of vaccine (25 μg or 50 μg RBD protein/dose, containing the aluminium-based adjuvant), the aluminium-based adjuvant or a sodium chloride injection administered intramuscularly on days 21 and 7 prior to mating and on gestation day (GD) 6. In Study 2 (pre- and postnatal developmental toxicity, PPND), ZF2001 at a dose of 25 μg RBD protein/dose or sodium chloride injection was administered intramuscularly to female rats ( n = 28 per group) 7 days prior to mating and on GD 6, GD 20 and postnatal day (PND) 10. There were no obvious adverse effects in dams, except for local injection site reactions related to the aluminium-based adjuvant (yellow nodular deposits in the interstitial muscle fibres). There were also no effects of ZF2001 on the mating performance, fertility or reproductive performance of parental females, embryo-fetal development, postnatal survival, growth, physical development, reflex ontogeny, behavioural and neurofunctional development, or reproductive performance of the offspring. The strong immune responses associated with binding and neutralising antibodies were both confirmed in dams and fetuses or offspring in these two studies. These results would support clinical trials or the use of ZF2001 in maternal immunisation campaigns, including those involving women with childbearing potential, regardless of pregnancy status. |
ArticleNumber | 74 |
Author | Dai, Lianpan Liu, Jing Chen, Guoyu Song, Yisheng Shao, Jinjin Lv, Wanqiang Tian, Ruiyu Zhang, Chengda Huang, Enqi Zhang, Lili Gao, George F. Zhang, Lijiang She, Guangbiao Wang, Jiahong |
Author_xml | – sequence: 1 givenname: Yisheng surname: Song fullname: Song, Yisheng organization: Center of Safety Evaluation and Research, Hangzhou Medical College, Key Laboratory of Drug Safety Evaluation and Research of Zhejiang Province, Hangzhou Medical College (Zhejiang Academy of Medical Sciences), Engineering Research Center of Novel Vaccine of Zhejiang Province, Hangzhou Medical College – sequence: 2 givenname: Jinjin surname: Shao fullname: Shao, Jinjin organization: Center of Safety Evaluation and Research, Hangzhou Medical College, Key Laboratory of Drug Safety Evaluation and Research of Zhejiang Province, Hangzhou Medical College (Zhejiang Academy of Medical Sciences), Engineering Research Center of Novel Vaccine of Zhejiang Province, Hangzhou Medical College – sequence: 3 givenname: Guangbiao surname: She fullname: She, Guangbiao organization: Anhui Zhifei Longcom Biopharmaceutical Co., Ltd – sequence: 4 givenname: Wanqiang orcidid: 0000-0001-8620-8889 surname: Lv fullname: Lv, Wanqiang organization: Center of Safety Evaluation and Research, Hangzhou Medical College, Key Laboratory of Drug Safety Evaluation and Research of Zhejiang Province, Hangzhou Medical College (Zhejiang Academy of Medical Sciences), Engineering Research Center of Novel Vaccine of Zhejiang Province, Hangzhou Medical College – sequence: 5 givenname: Guoyu surname: Chen fullname: Chen, Guoyu organization: Center of Safety Evaluation and Research, Hangzhou Medical College, Key Laboratory of Drug Safety Evaluation and Research of Zhejiang Province, Hangzhou Medical College (Zhejiang Academy of Medical Sciences), Engineering Research Center of Novel Vaccine of Zhejiang Province, Hangzhou Medical College – sequence: 6 givenname: Jing surname: Liu fullname: Liu, Jing organization: Center of Safety Evaluation and Research, Hangzhou Medical College, Key Laboratory of Drug Safety Evaluation and Research of Zhejiang Province, Hangzhou Medical College (Zhejiang Academy of Medical Sciences), Engineering Research Center of Novel Vaccine of Zhejiang Province, Hangzhou Medical College – sequence: 7 givenname: Lili surname: Zhang fullname: Zhang, Lili organization: Center of Safety Evaluation and Research, Hangzhou Medical College, Key Laboratory of Drug Safety Evaluation and Research of Zhejiang Province, Hangzhou Medical College (Zhejiang Academy of Medical Sciences), Engineering Research Center of Novel Vaccine of Zhejiang Province, Hangzhou Medical College – sequence: 8 givenname: Chengda surname: Zhang fullname: Zhang, Chengda organization: Center of Safety Evaluation and Research, Hangzhou Medical College, Key Laboratory of Drug Safety Evaluation and Research of Zhejiang Province, Hangzhou Medical College (Zhejiang Academy of Medical Sciences), Engineering Research Center of Novel Vaccine of Zhejiang Province, Hangzhou Medical College – sequence: 9 givenname: Jiahong surname: Wang fullname: Wang, Jiahong organization: Center of Safety Evaluation and Research, Hangzhou Medical College, Key Laboratory of Drug Safety Evaluation and Research of Zhejiang Province, Hangzhou Medical College (Zhejiang Academy of Medical Sciences), Engineering Research Center of Novel Vaccine of Zhejiang Province, Hangzhou Medical College – sequence: 10 givenname: Ruiyu surname: Tian fullname: Tian, Ruiyu organization: Center of Safety Evaluation and Research, Hangzhou Medical College, Key Laboratory of Drug Safety Evaluation and Research of Zhejiang Province, Hangzhou Medical College (Zhejiang Academy of Medical Sciences), Engineering Research Center of Novel Vaccine of Zhejiang Province, Hangzhou Medical College – sequence: 11 givenname: Lianpan orcidid: 0000-0001-8352-1327 surname: Dai fullname: Dai, Lianpan organization: CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences – sequence: 12 givenname: George F. orcidid: 0000-0002-3869-615X surname: Gao fullname: Gao, George F. organization: CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences – sequence: 13 givenname: Enqi surname: Huang fullname: Huang, Enqi email: huangenqi@zhifeishengwu.com organization: Anhui Zhifei Longcom Biopharmaceutical Co., Ltd – sequence: 14 givenname: Lijiang orcidid: 0000-0002-7902-0893 surname: Zhang fullname: Zhang, Lijiang email: 2020000087@hmc.edu.cn organization: Center of Safety Evaluation and Research, Hangzhou Medical College, Key Laboratory of Drug Safety Evaluation and Research of Zhejiang Province, Hangzhou Medical College (Zhejiang Academy of Medical Sciences), Engineering Research Center of Novel Vaccine of Zhejiang Province, Hangzhou Medical College |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37225729$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kjtvFDEUhS0URELIH6BAlmhCMeDHeMauENoQWClSGqCgsTx-LF7N2IvtWZF_jzcTQkJBZcv3u-f6XJ3n4CjEYAF4idFbjCh_l1vMWtwgQhuEup429Ak4IYiJBmHEjh7cj8FZzluEEO47ynr0DBzTnhDWE3ECthd2b8e4m2woaoQqGJjsLkUz6-L3Fpb4y2tfbmB0UNWSjtPggwoFVqhYH2Cehzn4AlfX39YXDRZwr7T2wcLz75ekDn0DK5RUyS_AU6fGbM_uzlPw9fLjl9Xn5ur603r14arR1VBpeoEZ1oZYTRAxbddZTbFSLUZKDMIRZ0in295ozhzTLeGEGzcMjKO6Fm04PQXrRddEtZW75CeVbmRUXt4-xLSRKhWvRys1w9wRhjvRqtZ1PafYWkEc0hjXVZGq9X7R2s3DZI2uW0pqfCT6uBL8D7mJe4kRQR3jB4XzO4UUf842Fzn5rO04qmDjnCXhWJCD576ir_9Bt3FOoe7qQHEmcPVaKbJQOsWck3X3v8FIHqIhl2jIGg15Gw1Ja9Orhz7uW_4EoQJ0AXIthY1Nf2f_R_Y3UWzEAw |
CitedBy_id | crossref_primary_10_1016_j_toxac_2024_03_096 crossref_primary_10_1080_07853890_2023_2261964 crossref_primary_10_1016_j_vaccine_2023_08_053 |
Cites_doi | 10.1038/s41577-020-00480-0 10.1016/j.yrtph.2021.105029 10.51362/neonatology.today/202171671115 10.1016/S1473-3099(21)00127-4 10.1016/j.cell.2020.10.043 10.1136/bmj.m3320 10.1172/JCI147553 10.1016/j.vaccine.2020.12.074 10.1002/rmv.2208 10.1016/j.ajog.2021.08.054 10.1016/S0264-410X(03)00357-8 10.1016/S0140-6736(21)02249-2 10.1016/j.ajogmf.2021.100481 10.1016/j.ajogmf.2021.100403 10.3390/v14030539 10.15585/mmwr.mm6944e3 10.1016/j.cell.2020.06.035 10.1016/S0140-6736(21)01429-X 10.1056/NEJMoa2202261 10.1056/NEJMoa0708630 10.1111/j.1741-4520.2009.00239.x 10.1172/JCI150790 10.1093/nsr/nwab193 10.1016/S0140-6736(20)32318-7 10.1016/j.jri.2020.103122 10.1016/j.reprotox.2021.05.007 10.1016/S0140-6736(21)02753-7 10.1080/22221751.2022.2056524 10.1016/j.ajog.2012.06.070 10.1016/S0140-6736(20)31029-1 |
ContentType | Journal Article |
Copyright | The Author(s) 2023 2023. The Author(s). The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: The Author(s) 2023 – notice: 2023. The Author(s). – notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | C6C NPM AAYXX CITATION 3V. 7RV 7X7 7XB 88C 8C1 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH K9- K9. KB0 M0R M0S M0T NAPCQ PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
DOI | 10.1038/s41541-023-00673-3 |
DatabaseName | Springer Open Access PubMed CrossRef ProQuest Central (Corporate) ProQuest Nursing & Allied Health Database ProQuest_Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) ProQuest Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials ProQuest Central ProQuest One Community College Coronavirus Research Database ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Consumer Health Database Health & Medical Collection (Alumni Edition) ProQuest Healthcare Administration Database Nursing & Allied Health Premium Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Open Access: DOAJ - Directory of Open Access Journals |
DatabaseTitle | PubMed CrossRef Publicly Available Content Database ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Family Health (Alumni Edition) ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Public Health ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Health Management Coronavirus Research Database ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | PubMed Publicly Available Content Database CrossRef |
Database_xml | – sequence: 1 dbid: C6C name: Springer Open Access url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: Directory of Open Access Journals - May need to register for free articles url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Public Health Pharmacy, Therapeutics, & Pharmacology |
EISSN | 2059-0105 |
EndPage | 74 |
ExternalDocumentID | oai_doaj_org_article_c518f251694a4f67831ee92f0c113572 10_1038_s41541_023_00673_3 37225729 |
Genre | Journal Article |
GrantInformation_xml | – fundername: National Key R&D Program of China (2018YFA0903200, 2020YFC0842300) Key R&D Program of Zhejiang Province (2020C03053, 2021C03077) – fundername: ; |
GroupedDBID | 0R~ 53G 5VS 7RV 7X7 8C1 8FI 8FJ AAJSJ ABUWG ACGFS ACSMW ADBBV AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BCNDV BENPR C6C CCPQU EBLON EBS ECGQY FYUFA GROUPED_DOAJ HMCUK HYE K9- KQ8 M0R M0T M~E NAO NAPCQ OK1 PGMZT PIMPY RNT RPM SNYQT UKHRP NPM AAYXX CITATION 3V. 7XB 8FK COVID DWQXO K9. PQEST PQQKQ PQUKI PRINS 7X8 AFGXO 5PM |
ID | FETCH-LOGICAL-c541t-79151cd2ec202d466ec31aa410a9b9f2fd26c47dc85f5c42828dfbb580038cd83 |
IEDL.DBID | RPM |
ISSN | 2059-0105 |
IngestDate | Fri Oct 04 13:07:21 EDT 2024 Tue Sep 17 21:31:41 EDT 2024 Fri Aug 16 09:16:59 EDT 2024 Thu Oct 10 22:57:18 EDT 2024 Fri Aug 23 02:18:01 EDT 2024 Sat Sep 28 08:18:43 EDT 2024 Fri Oct 11 20:45:40 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | 2023. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c541t-79151cd2ec202d466ec31aa410a9b9f2fd26c47dc85f5c42828dfbb580038cd83 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-7902-0893 0000-0002-3869-615X 0000-0001-8620-8889 0000-0001-8352-1327 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206582/ |
PMID | 37225729 |
PQID | 2818591828 |
PQPubID | 4669711 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_c518f251694a4f67831ee92f0c113572 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10206582 proquest_miscellaneous_2819279157 proquest_journals_2818591828 crossref_primary_10_1038_s41541_023_00673_3 pubmed_primary_37225729 springer_journals_10_1038_s41541_023_00673_3 |
PublicationCentury | 2000 |
PublicationDate | 2023-05-24 |
PublicationDateYYYYMMDD | 2023-05-24 |
PublicationDate_xml | – month: 05 year: 2023 text: 2023-05-24 day: 24 |
PublicationDecade | 2020 |
PublicationPlace | London |
PublicationPlace_xml | – name: London – name: England |
PublicationTitle | npj vaccines |
PublicationTitleAbbrev | npj Vaccines |
PublicationTitleAlternate | NPJ Vaccines |
PublicationYear | 2023 |
Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
References | TanrioverMDEfficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in TurkeyLancet20213982132221:CAS:528:DC%2BB3MXhsFGgs7zK10.1016/S0140-6736(21)01429-X342463588266301 BowmanCJLack of effects on female fertility and prenatal and postnatal offspring development in rats with BNT162b2, a mRNA-based COVID-19 vaccineReprod. Toxicol.202110328351:CAS:528:DC%2BB3MXht1SltL%2FJ10.1016/j.reprotox.2021.05.007340585738163337 DaiLGaoGFViral targets for vaccines against COVID-19Nat. Rev. Immunol.20212173821:CAS:528:DC%2BB3MXktFeksg%3D%3D10.1038/s41577-020-00480-033340022 TrostleMEAguero-RosenfeldMERomanASLighterJLHigh antibody levels in cord blood from pregnant women vaccinated against COVID-19Am. J. Obstet. Gynecol. MFM202131004811:CAS:528:DC%2BB3MXit1Whs7nE10.1016/j.ajogmf.2021.100481345626368455300 BeigiRHThe need for inclusion of pregnant women in COVID-19 vaccine trialsVaccine2021398688701:CAS:528:DC%2BB3MXhslWksL8%3D10.1016/j.vaccine.2020.12.074334463857798437 LiuHWhy are pregnant women susceptible to COVID-19? An immunological viewpointJ. Reprod. Immunol.20201391031221:CAS:528:DC%2BB3cXmt1Shsr8%3D10.1016/j.jri.2020.103122322441667156163 World Health Organization.WHO guidelines on nonclinical evaluation of vaccinesWHO Tech. Rep. Ser.20059273163 ZamanKEffectiveness of maternal influenza immunization in mothers and infantsN. Engl J. Med.2008359155515641:CAS:528:DC%2BD1cXht1WgsLjE10.1056/NEJMoa070863018799552 DesaiPKaurGDongFRodriguezMCOVID-19 vaccine acceptance in pregnancyNeonatol. Today202116111510.51362/neonatology.today/202171671115 ZambranoLDUpdate: Characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status - United States, January 22-October 3, 2020Morb. Mortal. Wkly Rep.202069164116471:CAS:528:DC%2BB3cXisFGhtLnF10.15585/mmwr.mm6944e3 HalperinSAFinal efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trialLancet20223992372481:CAS:528:DC%2BB38Xislemsg%3D%3D10.1016/S0140-6736(21)02753-734953526 NamdariRSpecies selection for nonclinical safety assessment of drug candidates: examples of current industry practiceRegul. Toxicol. Pharmacol.20211261050291:CAS:528:DC%2BB38XhvVWlsb8%3D10.1016/j.yrtph.2021.10502934455009 MakrisSLTerminology of developmental abnormalities in common laboratory mammals (version 2)Congenit. Anom.20094912324610.1111/j.1741-4520.2009.00239.x De Rose, D. U., Salvatori, G., Dotta, A. & Auriti, C. SARS-CoV-2 vaccines during pregnancy and breastfeeding: a systematic review of maternal and neonatal outcomes. Viruses14, https://doi.org/10.3390/v14030539 (2022). Dai, L. et al. Efficacy and safety of the RBD-dimer-based Covid-19 vaccine ZF2001 in adults. N. Engl. J. Med.https://doi.org/10.1056/NEJMoa2202261 (2022). ICH. ICH Harmonised Guideline S5(R3): detection of reproductive and developmental toxicity for human pharmaceuticals. (2020). BardaNEffectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational studyLancet2021398209321001:CAS:528:DC%2BB3MXisVahsr%2FP10.1016/S0140-6736(21)02249-2347561848555967 YangSSafety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trialsLancet Infect. Dis.2021211107111910.1016/S1473-3099(21)00127-4337731117990482 AlloteyJClinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysisBMJ2020370m332010.1136/bmj.m332032873575 US Food and Drug Administration. Guidance for industry: considerations for developmental toxicity studies for preventive and therapeutic vaccines for infectious disease indications. (2006). JamiesonDJKissinDMBridgesCBRasmussenSABenefits of influenza vaccination during pregnancy for pregnant womenAm. J. Obstet. Gynecol.2012207S17S2010.1016/j.ajog.2012.06.070229200534552345 World Health Organization. https://www.who.int/. GaoGFScience-based COVID-19 vaccine developmentNatl Sci. Rev.20218nwab1931:CAS:528:DC%2BB3MXisFCrsr7N10.1093/nsr/nwab193348586198566181 WhiteheadCLWalkerSPConsider pregnancy in COVID-19 therapeutic drug and vaccine trialsLancet2020395e921:CAS:528:DC%2BB3cXptlKmsLg%3D10.1016/S0140-6736(20)31029-1324107587220166 JafariMClinical characteristics and outcomes of pregnant women with COVID-19 and comparison with control patients: a systematic review and meta-analysisRev. Med. Virol.2021311161:CAS:528:DC%2BB3MXitVOlt7fL10.1002/rmv.220833387448 AnYA tandem-repeat dimeric RBD protein-based Covid-19 vaccine zf2001 protects mice and nonhuman primatesEmerg. Microbes Infect.202211105810711:CAS:528:DC%2BB38XhtV2qs7fO10.1080/22221751.2022.2056524353114939009945 DaiLA universal design of betacoronavirus vaccines against COVID-19, MERS, and SARSCell2020182722733.e111:CAS:528:DC%2BB3cXhtlGmsb3J10.1016/j.cell.2020.06.035326453277321023 JamiesonDJRasmussenSAAn update on COVID-19 and pregnancyAm. J. Obstet. Gynecol.20222261771861:CAS:528:DC%2BB3MXitlarurvJ10.1016/j.ajog.2021.08.05434534497 Burd, I., Kino, T. & Segars, J. The Israeli study of Pfizer BNT162b2 vaccine in pregnancy: considering maternal and neonatal benefits. J. Clin. Invest.131https://doi.org/10.1172/JCI150790 (2021). WallsACElicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2Cell202018313671382.e171:CAS:528:DC%2BB3cXit12ks7jL10.1016/j.cell.2020.10.043331604467604136 Klein, S. L., Creisher, P. S. & Burd, I. COVID-19 vaccine testing in pregnant females is necessary. J. Clin. Invest.131https://doi.org/10.1172/JCI147553 (2021). GruberMFMaternal immunization: US FDA regulatory considerationsVaccine2003213487349110.1016/S0264-410X(03)00357-812850366 SuttonDCOVID-19 vaccine acceptance among pregnant, breastfeeding, and nonpregnant reproductive-aged womenAm. J. Obstet. Gynecol. MFM202131004031:CAS:528:DC%2BB3MXhs1Clu7rK10.1016/j.ajogmf.2021.100403340489658146275 AndersonRMVegvariCTruscottJCollyerBSChallenges in creating herd immunity to SARS-CoV-2 infection by mass vaccinationLancet2020396161416161:CAS:528:DC%2BB3cXitlCmurzN10.1016/S0140-6736(20)32318-7331598507836302 M Jafari (673_CR11) 2021; 31 H Liu (673_CR9) 2020; 139 673_CR32 RH Beigi (673_CR27) 2021; 39 673_CR1 MD Tanriover (673_CR5) 2021; 398 CL Whitehead (673_CR33) 2020; 395 R Namdari (673_CR25) 2021; 126 N Barda (673_CR3) 2021; 398 S Yang (673_CR6) 2021; 21 673_CR28 673_CR26 SL Makris (673_CR34) 2009; 49 SA Halperin (673_CR4) 2022; 399 AC Walls (673_CR17) 2020; 183 K Zaman (673_CR29) 2008; 359 DJ Jamieson (673_CR10) 2022; 226 RM Anderson (673_CR8) 2020; 396 CJ Bowman (673_CR23) 2021; 103 P Desai (673_CR14) 2021; 16 673_CR24 L Dai (673_CR16) 2020; 182 World Health Organization. (673_CR20) 2005; 927 673_CR21 Y An (673_CR18) 2022; 11 LD Zambrano (673_CR12) 2020; 69 673_CR19 L Dai (673_CR15) 2021; 21 D Sutton (673_CR7) 2021; 3 GF Gao (673_CR2) 2021; 8 MF Gruber (673_CR22) 2003; 21 J Allotey (673_CR13) 2020; 370 DJ Jamieson (673_CR30) 2012; 207 ME Trostle (673_CR31) 2021; 3 |
References_xml | – volume: 21 start-page: 73 year: 2021 ident: 673_CR15 publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-020-00480-0 contributor: fullname: L Dai – volume: 126 start-page: 105029 year: 2021 ident: 673_CR25 publication-title: Regul. Toxicol. Pharmacol. doi: 10.1016/j.yrtph.2021.105029 contributor: fullname: R Namdari – volume: 16 start-page: 11 year: 2021 ident: 673_CR14 publication-title: Neonatol. Today doi: 10.51362/neonatology.today/202171671115 contributor: fullname: P Desai – volume: 21 start-page: 1107 year: 2021 ident: 673_CR6 publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(21)00127-4 contributor: fullname: S Yang – volume: 183 start-page: 1367 year: 2020 ident: 673_CR17 publication-title: Cell doi: 10.1016/j.cell.2020.10.043 contributor: fullname: AC Walls – volume: 370 start-page: m3320 year: 2020 ident: 673_CR13 publication-title: BMJ doi: 10.1136/bmj.m3320 contributor: fullname: J Allotey – ident: 673_CR26 doi: 10.1172/JCI147553 – volume: 39 start-page: 868 year: 2021 ident: 673_CR27 publication-title: Vaccine doi: 10.1016/j.vaccine.2020.12.074 contributor: fullname: RH Beigi – volume: 31 start-page: 1 year: 2021 ident: 673_CR11 publication-title: Rev. Med. Virol. doi: 10.1002/rmv.2208 contributor: fullname: M Jafari – ident: 673_CR21 – volume: 226 start-page: 177 year: 2022 ident: 673_CR10 publication-title: Am. J. Obstet. Gynecol. doi: 10.1016/j.ajog.2021.08.054 contributor: fullname: DJ Jamieson – volume: 21 start-page: 3487 year: 2003 ident: 673_CR22 publication-title: Vaccine doi: 10.1016/S0264-410X(03)00357-8 contributor: fullname: MF Gruber – volume: 398 start-page: 2093 year: 2021 ident: 673_CR3 publication-title: Lancet doi: 10.1016/S0140-6736(21)02249-2 contributor: fullname: N Barda – volume: 3 start-page: 100481 year: 2021 ident: 673_CR31 publication-title: Am. J. Obstet. Gynecol. MFM doi: 10.1016/j.ajogmf.2021.100481 contributor: fullname: ME Trostle – volume: 3 start-page: 100403 year: 2021 ident: 673_CR7 publication-title: Am. J. Obstet. Gynecol. MFM doi: 10.1016/j.ajogmf.2021.100403 contributor: fullname: D Sutton – ident: 673_CR32 doi: 10.3390/v14030539 – volume: 69 start-page: 1641 year: 2020 ident: 673_CR12 publication-title: Morb. Mortal. Wkly Rep. doi: 10.15585/mmwr.mm6944e3 contributor: fullname: LD Zambrano – volume: 182 start-page: 722 year: 2020 ident: 673_CR16 publication-title: Cell doi: 10.1016/j.cell.2020.06.035 contributor: fullname: L Dai – volume: 398 start-page: 213 year: 2021 ident: 673_CR5 publication-title: Lancet doi: 10.1016/S0140-6736(21)01429-X contributor: fullname: MD Tanriover – ident: 673_CR24 – ident: 673_CR19 doi: 10.1056/NEJMoa2202261 – volume: 359 start-page: 1555 year: 2008 ident: 673_CR29 publication-title: N. Engl J. Med. doi: 10.1056/NEJMoa0708630 contributor: fullname: K Zaman – ident: 673_CR1 – volume: 927 start-page: 31 year: 2005 ident: 673_CR20 publication-title: WHO Tech. Rep. Ser. contributor: fullname: World Health Organization. – volume: 49 start-page: 123 year: 2009 ident: 673_CR34 publication-title: Congenit. Anom. doi: 10.1111/j.1741-4520.2009.00239.x contributor: fullname: SL Makris – ident: 673_CR28 doi: 10.1172/JCI150790 – volume: 8 start-page: nwab193 year: 2021 ident: 673_CR2 publication-title: Natl Sci. Rev. doi: 10.1093/nsr/nwab193 contributor: fullname: GF Gao – volume: 396 start-page: 1614 year: 2020 ident: 673_CR8 publication-title: Lancet doi: 10.1016/S0140-6736(20)32318-7 contributor: fullname: RM Anderson – volume: 139 start-page: 103122 year: 2020 ident: 673_CR9 publication-title: J. Reprod. Immunol. doi: 10.1016/j.jri.2020.103122 contributor: fullname: H Liu – volume: 103 start-page: 28 year: 2021 ident: 673_CR23 publication-title: Reprod. Toxicol. doi: 10.1016/j.reprotox.2021.05.007 contributor: fullname: CJ Bowman – volume: 399 start-page: 237 year: 2022 ident: 673_CR4 publication-title: Lancet doi: 10.1016/S0140-6736(21)02753-7 contributor: fullname: SA Halperin – volume: 11 start-page: 1058 year: 2022 ident: 673_CR18 publication-title: Emerg. Microbes Infect. doi: 10.1080/22221751.2022.2056524 contributor: fullname: Y An – volume: 207 start-page: S17 year: 2012 ident: 673_CR30 publication-title: Am. J. Obstet. Gynecol. doi: 10.1016/j.ajog.2012.06.070 contributor: fullname: DJ Jamieson – volume: 395 start-page: e92 year: 2020 ident: 673_CR33 publication-title: Lancet doi: 10.1016/S0140-6736(20)31029-1 contributor: fullname: CL Whitehead |
SSID | ssj0001763570 |
Score | 2.2959962 |
Snippet | ZF2001, a protein subunit vaccine against coronavirus disease 2019 (COVID-19), contains recombinant tandem repeat of dimeric receptor-binding domain (RBD)... Abstract ZF2001, a protein subunit vaccine against coronavirus disease 2019 (COVID-19), contains recombinant tandem repeat of dimeric receptor-binding domain... Abstract ZF2001, a protein subunit vaccine against coronavirus disease 2019 (COVID-19), contains recombinant tandem repeat of dimeric receptor-binding domain... |
SourceID | doaj pubmedcentral proquest crossref pubmed springer |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 74 |
SubjectTerms | 631/154/1438 692/308/153 Aluminum Biomedical and Life Sciences Biomedicine Coronaviruses COVID-19 COVID-19 vaccines Embryos Females Fertility Immunization Infectious Diseases Injection Medical Microbiology Offspring Proteins Public Health Reproduction Severe acute respiratory syndrome coronavirus 2 Sodium chloride Toxicity Vaccine Vaccines Virology |
SummonAdditionalLinks | – databaseName: Open Access: DOAJ - Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Jb9QwFLZQT1wQO4GCjIQqEGM13hL7CIVRQQJ6aFHFxfKqDhIZRGYQ_fc8O5mNRVy4xk709PaX9_wZoSc1j22efiIQnhQRiXNic7tQaspd42RIZYjm3fvm-Ey8PZfnW1d95ZmwAR54YNyhl1Qllrs5wooErpXTGDVLtaeUy3bwvlRuFVPl70rBWavHUzI1V4c9RCoBlTPjpFzOQvhOJCqA_X_KMn8flvylY1oC0fQ6ujZmkPjFQPkNdCV2N9HByQBBfTnBp5sTVf0EH-CTDTj15S30eWtKCL5iu4AzrmWBfQXHhxfzHzMPmTmeJ2xxLpe_uDIsgwuiw6zD_dItwQ_gow8f37wiVOPv1ufuPH76aZpHp55h2AR61d9GZ9PXp0fHZLxvgXhgzSIjV0rqA4ue1SyIpomeU2sFra12OrEUWONFG7ySSXqRi7WQnJMqtxd9UPwO2uvmXbyHcJTcQSWjo_ZKUHgdZJ6LG1YHl6_6qNDzFe_N1wFWw5R2OFdmkJQBSZkiKcMr9DKLZ70zQ2KXB6AoZlQU8y9FqdD-SrhmtNPeFCwsDTWWqtDj9TJYWG6b2C7Ol2WPZpk3bYXuDrqwpoS34A-hPqmQ2tGSHVJ3V7rZRUHxhswup39A12SlUBu6_s6L-_-DFw_QVVYsQRIm9tHe4tsyPoTkauEeFTv6CZraHCs priority: 102 providerName: Directory of Open Access Journals – databaseName: Coronavirus Research Database dbid: COVID link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9QwFLZgeuHCvgQKMhKqQIzbxEvGOSEojAoS0EOLKi5WvMGASEqTIMqv59lJZpiyHLgmTuTl81v8nr-H0IOUuVnIfiKgniThnjFShnChKDKmcy2sj0k0r9_ke4f81ZE4Gg7cmiGtcpSJUVDb2oQz8p3IWlSANSyfHH8loWpUiK4OJTTOow0mwdOZoI3dt-9ePl-dskS-tXS4LZMyudOAxuLgQVNGYpEWwtY0UiTu_5O1-XvS5JnIaVRI80tIjUPp81A-b3et3jY_zrA8_v9YL6OLg62Kn_bguoLOueoq2trvya5Pp_hgdXermeItvL-iwT69hj79ko8EfykriwODZiSYBRGL2_r7woAPgGuPSxwc8y86puXgyB2xqHDT6Q4kDo6TTbICfytNyAPAD9_PQ5LWIwyNAMHNdXQ4f3Gwu0eGyg7EwOS3gSNTZMZSZ2hKLc9zZ1hWljxLy0IXnnpLc8Nn1kjhheHBLbReayFDINNYyW6gSVVX7hbCTjANPlPhCiN5Bp8DuoIbRVOrQ1GRBD0eV1cd9wQeKgbemVQ9FhRgQUUsKJagZwEAy5aBfDs-qE8-qGEvKyMy6WkIMPKSe9D2LHOuoD41WQZoownaHJdVDRKhUas1TdD95WvYyyFAU1au7mKbgoa5mSXoZo-2ZU_YDCQveEIJkms4XOvq-ptq8THyhYMNGQxN6Nd0hOyqX3-fi9v_HsYddIHGXSQI5Zto0p507i4YaK2-N-zCn1aXOXo priority: 102 providerName: ProQuest – databaseName: Springer Open Access dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9QwDLdgvCChCcZXYaAgoQnEVWu-eukjHJwGErCHDU28RE2aiEOiN9E7xP577LR3x8F44LVJKiu2Yzu2fwF4WsgwpuqnHM2TyVWUMq8pXagrLl3pdBNTEc37D-XRqXp3ps8GmBzqhdnK30tz2KGBURjwCpmnN1VyeRWuaV4WJMGTcrK5T0nIasXQF3P50i3bkyD6L_Mr_y6P_CNHmkzP9CbsDj4je9kz-RZcCe0eHBz3oNMXI3ay6aHqRuyAHW_gqC_24EZ_M8f6hqPb8PW3OiH8a902jJAtE_ArHn1sMf858-ibs3lkNaOA-ZtL5TIsYTrMWtYt3RJPAjb5-Ont65xX7EftKT_Pnn2eUvHUc4aTULK6O3A6fXMyOcqHFxdyj1u1IOxKzX0jgheFaFRZBi95XSte1JWrooiNKL0aN97oqL2icK2JzmlDCUbfGHkXdtp5G-4DC1o6jGWqUHmjOC5HrlN4I4rG0WMfGbxY8cKe98AaNiXEpbE95yxyzibOWZnBK2LXeiaBYqcPKCt20DHrNTdRUOJP1SqiFZY8hErEwnOOsiEy2F8x2w6a2tmEhlVhlGUyeLIeRh2jxEndhvkyzakE7c04g3u9bKwpkWM8ETFCycBsSc0Wqdsj7exLwvFG344cQKRrtBKwDV3_3osH_zf9IVwXSQd0LtQ-7Cy-L8MjdKQW7nHSoF9SxxLJ priority: 102 providerName: Springer Nature |
Title | Developmental and reproductive toxicity of a recombinant protein subunit COVID-19 vaccine (ZF2001) in rats |
URI | https://link.springer.com/article/10.1038/s41541-023-00673-3 https://www.ncbi.nlm.nih.gov/pubmed/37225729 https://www.proquest.com/docview/2818591828 https://search.proquest.com/docview/2819279157 https://pubmed.ncbi.nlm.nih.gov/PMC10206582 https://doaj.org/article/c518f251694a4f67831ee92f0c113572 |
Volume | 8 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELe28cIL4pvAqIyEJhDNGn8kcR5ZWDVAGwVtqOIlih1nFNFkWlrE_nvOl6Rd-XjhJVJiJ7F8v8vd5c4_E_I8EDZ21U8-mCfly1IIP3fpwjBhQkc6LEosojk-iY7O5LtpON0iUb8WBov2jZ7tV9_n-9XsK9ZWXszNqK8TG02OUzCKznLy0TbZjoW4FqPjnxXkWAu6FTKBUKMGrJSEqJkLHzdm8d3uOSIGKLeu5dogIW__35zNP2smf0ucoj0a3ya3OkeSvm4HfIds2eou2Zu0TNRXQ3q6XljVDOkenaw5qq_ukW_XioXgKXlVUEdvieyv8P2ji_rnzICDTuuS5tRFzXONNTMUiR1mFW2WegmfA5p--Pz2jc8S-iM3LklPX3wZuwqqlxQ6Abya--RsfHiaHvndtgu-gVlaOALLkJmCW8MDXsgoskawPJcsyBOdlLwseGRkXBgVlqGRLmYrSq1D5bKMplDiAdmp6so-ItSGQkNAk9jEKMngdhC9i3F4UGi344dHXvVzn1207BoZZsWFylqhZSC0DIWWCY8cOPGsejpmbLxQX55nHT4yEzJVcpf9k7kswRQLZm3Cy8AwBrDgHtnthZt16tpkSImVQKilPPJs1QyK5rIneWXrJfZJuJub2CMPWyysRtJjySNqAyUbQ91sAWwjmXePZY8Me0Ctx_XvuXj8_296Qm5yVIXQ53KX7Cwul_YpeFYLPQB1msZwVCkbkBsHhyeTT3CWRimcIZwG-M8Cju8_qgGq3S-iDSYE |
link.rule.ids | 230,315,733,786,790,870,891,2115,12083,12250,21416,27955,27956,31752,31753,33299,33300,33777,33778,38549,41153,42222,43343,43612,43838,43928,51609,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB7B9gAX3o9AASOhCsSmTWwn65wQFFZbaEsPW1RxsWLHgQWRlCZBlF_P2Ek2bHkcuCZO5MfneXjG3wA8CpiZ2OwnH9WT8HnOmJ_acGGUhEzFKspyl0Sztx_PDvnro-ioO3CrurTKXiY6QZ2V2p6RbznWogStYfHs-Ktvq0bZ6GpXQuM8rKFipWIEa9tv3-28HE5ZHN9a0N2WCZjYqlBjcfSgKfNdkRafrWgkR9z_J2vz96TJM5FTp5Cml0H2Q2nzUD5vNrXa1D_OsDz-_1ivwKXOViXPW3BdhXOmuAYbBy3Z9emYzIe7W9WYbJCDgQb79Dp8-iUfCf-SFhmxDJqOYBZFLKnL7wuNPgApc5IS65h_US4thzjuiEVBqkY1KHGIm2w_TMi3VNs8APL4_dQmaT0h2AgRXN2Aw-mr-fbM7yo7-Bonv7YcmVGoM2o0DWjG49hoFqYpD4M0UUlO84zGmk8yLaI80ty6hVmuVCRsIFNngt2EUVEW5jYQEzGFPlNiEi14iJ8juqwbRYNM2aIiHjztV1cetwQe0gXemZAtFiRiQTosSObBCwuAZUtLvu0elCcfZLeXpY5CkVMbYOQpz1Hbs9CYhOaBDkNEG_VgvV9W2UmESg5r6sHD5WvcyzZAkxambFybhNq5mXhwq0XbsidsgpIXPSEPxAoOV7q6-qZYfHR84WhDWkMT-zXuITv06-9zceffw3gAF2bzvV25u7P_5i5cpG5HRT7l6zCqTxpzD421Wt3vduRPHPA8YQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB5BkRASQlBegQJGQhWIjZr4kXWOsGXV8ih7aFHVixW_YJFIqmYX0X_P2MnudqEcuCZ2ZHlmPDP5Zj4DvMiYG4bqpxTdk0y5ZyytAlwoypzpQgvrYxHNp4Ni74i_PxbHF7r4Y7X7ApLsehoCS1M92zm1vm8Slzstuh2OaTBlabxpJWVX4RrH4CbCtcVo9Zcl8q1lfbfM5VPXPFIk7r8s2vy7aPIP5DQ6pPFtuNVHkuRNJ_o7cMXVm7A96aiozwfkcNVZ1Q7INpmsSKrPN-Fm97-OdG1Id-H7heoh_GpVWxL4LiMdLB6IZNb8mhqM2EnjSUVCGv1DxyIaEpkepjVp53qO5wMZff6yv5vmJflZmYDak5cn41BS9YrgINS39h4cjd8djvbS_h6G1OBWzQKjpciNpc7QjFpeFM6wvKp4nlWlLj31lhaGD62RwgvDQxJnvdZCBtjRWMnuw0bd1O4hECeYxgyndKWRPMfpqAsh6aGZ1eEKkAReL2ShTju6DRVhciZVJzmFklNRcool8DaIazkyUGXHB83ZV9VbnjIil54GOJBX3KNvZrlzJfWZyXPUDZrA1kLYqrffVkWOrBJzL5nA8-VrtLwAp1S1a-ZxTEnD3gwTeNDpxnIlbIjnJOYtCcg1rVlb6vqbevotsntjxBfCQlzXYKFgq3X9ey8e_d_wZ3B9sjtWH_cPPjyGGzSag0gp34KN2dncPcFIa6afRmP6DQSAHfo |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Developmental+and+reproductive+toxicity+of+a+recombinant+protein+subunit+COVID-19+vaccine+%28ZF2001%29+in+rats&rft.jtitle=npj+vaccines&rft.au=Song%2C+Yisheng&rft.au=Shao%2C+Jinjin&rft.au=She%2C+Guangbiao&rft.au=Lv%2C+Wanqiang&rft.date=2023-05-24&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2059-0105&rft.volume=8&rft.issue=1&rft_id=info:doi/10.1038%2Fs41541-023-00673-3&rft.externalDocID=10_1038_s41541_023_00673_3 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2059-0105&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2059-0105&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2059-0105&client=summon |